Quantum Genesis AI Corp. (OTC: QGAI), a technology company specializing in artificial intelligence and computational modeling, has issued a statement regarding the Caveat Emptor designation placed on its securities by OTC Markets Group on February 12, 2026. The company has been actively communicating with OTC Markets to understand the basis for the designation, which has been attributed to a "public interest concern."
Since the designation, Quantum Genesis AI has sought clarification from OTC Markets and intends to continue cooperating to resolve the matter. OTC Markets recently informed the company that it may formally request a review of the designation starting March 13, 2026. Quantum Genesis AI plans to engage in the review process at the earliest opportunity.
CEO Naveen Kulkarni emphasized the company's commitment to transparency and cooperation, stating, "We take this matter seriously and are committed to working constructively with OTC Markets to better understand the basis for the designation. Our objective is to obtain clarity and take appropriate steps through the review process."
The company remains dedicated to maintaining transparency with shareholders and the investment community. It will continue to cooperate with OTC Markets and provide updates as more information becomes available. For further details, visit the company's website at www.qgaicorp.com and its OTC Markets profile at www.otcmarkets.com/stock/QGAI.
This announcement is significant as it addresses a regulatory action that can impact investor confidence and stock liquidity. The Caveat Emptor designation warns investors that there may be a public interest concern associated with the company, potentially affecting trading. Quantum Genesis AI's proactive response and initiation of the review process are critical steps toward restoring normal market conditions and investor trust.
The company's focus on AI and computational modeling positions it in a high-growth sector, making the resolution of this designation important for its future fundraising and partnership opportunities. The outcome of the review could set a precedent for how OTC Markets handles similar cases involving technology firms.
Investors and stakeholders should monitor the review process and any subsequent disclosures from the company. The situation underscores the importance of corporate governance and timely communication with regulators in maintaining market integrity.
